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Abstract
Background: The protein kinase GSK-3 is constitutively active in quiescent cells in the absence of growth factor signaling.
Previously, we identified a set of genes that required GSK-3 to maintain their repression during quiescence. Computational
analysis of the upstream sequences of these genes predicted transcription factor binding sites for CREB, NFkB and AP-1. In
our previous work, contributions of CREB and NFkB were examined. In the current study, the AP-1 component of the
signaling network in quiescent cells was explored.
Methodology/Principal Findings: Using chromatin immunoprecipitation analysis, two AP-1 family members, c-Jun and
JunD, bound to predicted upstream regulatory sequences in 8 of the 12 GSK-3-regulated genes. c-Jun was phosphorylated
on threonine 239 by GSK-3 in quiescent cells, consistent with previous studies demonstrating inhibition of c-Jun by GSK-3.
Inhibition of GSK-3 attenuated this phosphorylation, resulting in the stabilization of c-Jun. The association of c-Jun with its
target sequences was increased by growth factor stimulation as well as by direct GSK-3 inhibition. The physiological role for
c-Jun was also confirmed by siRNA inhibition of gene induction.
Conclusions/Significance: These results indicate that inhibition of c-Jun by GSK-3 contributes to the repression of growth
factor-inducible genes in quiescent cells. Together, AP-1, CREB and NFkB form an integrated transcriptional network that is
largely responsible for maintaining repression of target genes downstream of GSK-3 signaling.
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Introduction
The serine/threonine kinase glycogen synthase kinase-3 (GSK-
3) is a master regulator of a variety of cellular processes. First
characterized as the kinase responsible for phosphorylating and
inactivating glycogen synthase, GSK-3 now has recognized roles
in controlling cell proliferation, survival and differentiation.
Abnormal GSK-3 regulation has been associated with many
human diseases including diabetes, heart disease, cancer, Alzhei-
mer’s disease and schizophrenia [1,2,3].
GSK-3 has two widely expressed mammalian isoforms, GSK-
3a and GSK-3b, both of which are subject to regulation by the PI
3-kinase/Akt pathway [4]. GSK-3 has been shown to regulate cell
survival and proliferation downstream of PI 3-kinase signaling
through phosphorylation of cyclin D1 [5], Mcl-1 [6], and
eukaryotic translation initiation factor 2B (eIF2B) [7,8], as well
as a variety of transcription factors [1,3]. GSK-3 is also regulated
through the Wnt pathway. Wnt signaling results in a decrease in
the phosphorylation of b-catenin by GSK-3, causing a corre-
sponding increase in the transcriptional activation of b-catenin/
TCF target genes [9].
Unlike most protein kinases, GSK-3 is constitutively active in
quiescent cells, and undergoes an inhibitory phosphorylation by
Akt (on serine 9 for GSK-3b, and on serine 21 for GSK-3a) in the
presence of growth factors [4]. The activity of GSK-3 in quiescent
cells suggests that it may actively maintain repression of growth
factor-regulated genes in the absence of PI 3-kinase signaling. We
have investigated the role of GSK-3 in quiescence by combining
global expression profiling and computational analyses to examine
gene expression downstream of PI 3-kinase/Akt/GSK-3 signaling
[10]. These studies identified a set of twelve immediate early genes
whose induction following growth factor stimulation of quiescent
T98G human glioblastoma cells was dependent upon PI 3-kinase
and which could also be induced by direct inhibition of GSK-3
without growth factor stimulation [10,11]. These genes mainly
encoded growth factors and transcription factors involved in cell
proliferation, so their repression by GSK-3 presumably contrib-
uted to maintenance of the quiescent state of the cell.
The identification of a set of genes that required GSK-3 to
maintain their repression during quiescence allowed us to
investigate the transcriptional network downstream of GSK-3
signaling. Since the expression of co-regulated genes may be
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mediated by common transcription factors, we examined the
upstream sequences of the twelve GSK-3 repressed genes to
identify statistically over-represented and evolutionarily conserved
transcription factor binding sites. This computational analysis
predicted AP-1, as well as CREB and NFkB transcription factors,
as potential regulators of these genes downstream of GSK-3
[10,12].
In the present study, we have investigated the role of AP-1
family members in GSK-3 mediated transcriptional regulation.
Two AP-1 family members, c-Jun and JunD, bound to predicted
upstream regulatory sequences in 8 of the 12 GSK-3-regulated
genes. Consistent with previous studies demonstrating inhibition of
c-Jun by GSK-3 [13,14], c-Jun was phosphorylated by GSK-3 in
quiescent cells. The association of c-Jun with its target sequences
was increased by growth factor stimulation as well as by GSK-3
inhibition, and a physiological role for c-Jun was demonstrated by
siRNA inhibition of gene induction. These results indicate that
inhibition of c-Jun by GSK-3 contributes to the repression of
growth factor-regulated genes during quiescence. Moreover,
together with previous studies, these findings delineate an
integrated transcriptional network in which AP-1, CREB and
NFkB play major roles in GSK-3-mediated repression of target
genes in quiescent cells.
Results and Discussion
Binding of c-Jun to GSK-3 Target Genes
Our previous computational analysis identified a total of 22
conserved, putative AP-1 sites across all 12 of the genes that were
induced by inhibition of GSK-3 (Figure 1). The AP-1 family of
transcription factors is made up of three Jun family members (c-
Jun, JunB, and JunD) and four Fos family members (c-Fos, FosB,
Fra-1 and Fra-2). AP-1 is a dimeric transcription complex that is
formed from Jun-Jun family homodimers, or Jun-Fos family
heterodimers [15,16]. It is the particular combination of the
dimers that determines the transcriptional activity. FosB, c-Fos,
and c-Jun are activators, whereas JunD, JunB, Fra-1 and Fra-2
have weaker transactivation domains and can act as repressors by
competing for c-Fos, FosB and c-Jun binding. To determine which
family members are present in quiescent T98G cells, immunoblots
for all members were conducted. As expected, c-Fos, FosB, Fra-1
and Fra-2 were not detected in the quiescent cells, as they require
growth factor signaling for their induction [17,18,19,20] (data not
shown). c-Jun, JunD and JunB were all detected by immunoblots,
although JunB was only weakly detected (Figure 2A). c-Jun, JunD
and JunB therefore were pursued in subsequent chromatin
immunoprecipitation (ChIP) experiments.
We sought to determine if c-Jun was bound to these predicted
sites by ChIP analysis of quiescent T98G cells, as well as following
stimulation with platelet-derived growth factor (PDGF). T98G
cells were rendered quiescent as described in Materials and
Methods, and then stimulated for 30 minutes with PDGF, which
was the growth factor used in the initial studies of the PI 3-kinase/
Akt/GSK-3 regulated genes [11], from which the GSK-3
regulated subset was derived [10]. Eight of 12 genes (BHLHB2,
CTGF, CYR61, FOSB, NR4A1, NR4A2, PLAU, and RGS2)
demonstrated occupancy/binding by c-Jun (greater than 3-fold
as compared to the negative control promoter, MYOG) in both
untreated and PDGF treated samples (Figure 2B). PDGF
treatment resulted in a greater than 2-fold increase in binding of
c-Jun at 4 sites in 4 different genes (BHLHB2, NR4A2, PLAU and
RGS2) as well as a moderate increase in binding (1.6 fold) for
CTGF (Figure 2B and C). We next tested for binding and
recruitment of c-Jun following direct inhibition of GSK-3 with the
Figure 1. Conserved AP-1 sites predicted in the upstream regions of GSK-3 regulated genes. Predicted AP-1 binding sites are indicated
by vertical black lines in the 5-kb aligned sequences of human and mouse genes [10]. Numeric positions are relative to the transcription start site.
Positions of the ChIP PCR amplicons are indicated. Refer to Table S1 for precise positions of predicted sites and of primers. Alignments are indicated
as dark blue, match; orange, mismatch; white, aligned to gap.
doi:10.1371/journal.pone.0020150.g001
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Figure 2. Analysis of c-Jun binding and recruitment to predicted AP-1 sites by chromatin immunoprecipitation. A. Quiescent T98G cell
extracts were immunoblotted with anti-cJun, anti-JunB and anti-JunD antibodies. Images were taken from different parts of the same
autoradiography film, and therefore have identical exposures. Sizes indicated are in kDa. As expected, JunD has two protein products which run as a
40–50 kDa doublet B. Quiescent T98G cells were treated with PDGF for 30 minutes or left untreated (NT), and then chromatin was
immunoprecipitated with anti-c-Jun antibody or normal rabbit IgG. Only the PDGF-stimulated samples are plotted for the normal rabbit IgG
immunoprecipitates. The numbers in parentheses refer to the 59-most position of the putative AP-1 binding site (see Figure 1) relative to the
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small molecule inhibitor SB-216763 in the absence of growth
factor stimulation. Interestingly, inhibition of GSK-3 also resulted
in a greater than 2-fold increase in binding of c-Jun to the
upstream sites in CTGF, CYR61 and RGS2 (Figure 2C), indicating
a direct effect of GSK-3 on c-Jun. Overall, the predicted upstream
sequences of 8 out of 12 genes were bound by c-Jun and the
occupancy of c-Jun at 6 of these genes was increased following
either growth factor stimulation or direct inhibition of GSK-3.
Binding of JunD to GSK-3 Target Genes
JunD and JunB AP-1 family members have weaker activation
domains and can potentially act as repressors that antagonize or
inhibit the binding of activating family members [15,16]. We
therefore hypothesized that gene induction through AP-1 may be
the result of JunD and/or JunB being displaced by an activating
family member such as c-Jun. To test this, we conducted ChIP
analysis for both JunB and JunD at the predicted AP-1 sites
illustrated in Figure 1. JunB ChIP experiments did not show
binding or recruitment greater than that of the negative control
promoter, MYOG, or than that of the IgG control (data not
shown). In contrast, ChIP analysis for JunD indicated that for
many of the genes, JunD was bound to the upstream regions
(Figure 3). In all, 8 out of 12 genes showed JunD binding greater
than 3-fold as compared to the negative control promoter, MYOG.
For seven of the genes showing JunD binding (BHLHB2, CTGF,
CYR61, FOSB, NR4A1, PLAU, and RGS2), the relative binding of
the PDGF and untreated (NT) samples were not significantly
different, but both higher than that of the negative control,MYOG,
and of the control IgG sample. The eighth gene, NR4A2, showed
increased binding of JunD upon PDGF stimulation. Binding of
Figure 3. Analysis of JunD binding to predicted AP-1 sites by chromatin immunoprecipitation. Quiescent T98G cells were treated with
PDGF for 30 minutes or left untreated (NT), and then chromatin was immunoprecipitated with an anti-JunD antibody or normal rabbit IgG. Only the
PDGF-stimulated samples are plotted for normal rabbit IgG. The numbers in parentheses refer to the 59-most position of the putative AP-1 binding
site (see Figure 1) relative to the transcription start site. Data are presented as percent input averaged from 4 separate experiments 6 S.E. MYOG
served as a negative control promoter. * indicates greater than 3-fold binding compared to MYOG in both untreated and PDGF treated samples; #
indicates greater than 3-fold binding compared to MYOG in the PDGF treated sample only.
doi:10.1371/journal.pone.0020150.g003
transcription start site. When more than one position is listed, this refers to all possible sites that would be detected within the resolution limits of the
ChIP PCR amplicon (approximately 6250 nucleotides). For those genes with multiple putative AP-1 sites, only one representative site (if all were
negative for a given gene) or that site which indicated binding are shown for clarity. For a complete list of all tested sites, see Table S1. Data are
presented as percent input averaged from 4 separate experiments6 S.E. MYOG served as a negative control promoter. Asterisks indicate greater than
3-fold binding as compared to MYOG in both untreated and PDGF treated samples C. Recruitment of c-Jun upon stimulation with PDGF or direct
inhibition of GSK-3 with SB-216763. Quiescent T98G cells were treated with PDGF for 30 minutes or left untreated, or treated with SB-216763 for
1 hour or with DMSO vehicle control. Only those genes that initially showed c-Jun binding (panel A) are shown. Data are presented as fold change
over untreated (for PDGF) or fold change over DMSO vehicle control (for SB-216763), and are averaged from 4 separate experiments 6S.E. No
significant change was observed in the normal rabbit IgG or MYOG samples (not shown).
doi:10.1371/journal.pone.0020150.g002
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JunD to these 8 genes corresponded to 100% overlap with those
sites to which we demonstrated c-Jun binding (see Figure 2B).
These results suggested that JunD was occupying the same AP-1
sites as c-Jun, but with the exception of NR4A2, was not changing
in response to growth factor stimulation. This may reflect the
presence of c-Jun-JunD heterodimers at some or all of these AP-1
binding sites. Genes targeted by AP-1 may therefore be activated
by recruitment of the activating partner, c-Jun, or by posttrans-
lational modifications of the complex to stimulate target gene
expression.
Inhibition of GSK-3 Leads to Dephosphorylation and
Stabilization of c-Jun
Since the recruitment of c-Jun to its target sites was stimulated
by inhibition of GSK-3, we investigated the effect of GSK-3
inhibition on c-Jun phosphorylation. It has been previously shown
that GSK-3 phosphorylates c-Jun on threonine 239 [21]. This
phosphorylation event has been shown to block c-Jun DNA
binding activity [13] and transactivation [22], and target it for
ubiquitination and proteasomal degradation [14]. We therefore
assessed the phosphorylation status of c-Jun with the use of
phospho-specific antibodies (Figure 4A). Quiescent T98G cells
were treated for a time course up to 60 minutes with the GSK-3
inhibitor SB-216763, or the corresponding vehicle control, without
growth factor stimulation. This was the treatment time corre-
sponding to the gene inductions described previously [10]. As
expected, phosphorylation of c-Jun threonine 239 was readily
detectable in quiescent cells, consistent with the increased kinase
activity of GSK-3 [10,12]. As compared to the untreated sample
(NT), phosphorylation at threonine 239 decreased as rapidly as
15 minutes following addition of SB-216763, and declined for the
duration of the time course. The 60-minute vehicle control was
unchanged.
We next conducted a more extensive time course of GSK-3
inhibition to see if we could observe a stabilization of c-Jun
(Figure 4B). Quiescent T98G cells were again treated with SB-
216763 in the absence of growth factors. The levels of c-Jun
remained relatively unchanged until 2 hours, when a modest
increase in signal was observed as compared to the vehicle control.
The 4-hour time point showed a more marked increase in signal as
compared to the b-actin loading control, suggesting that the amount
of c-Jun protein had increased during the duration of the
experiment. This apparent increase in the c-Jun signal upon
dephosphorylation of threonine 239 would be consistent with a
stabilization of the protein previously described [14], and with the
corresponding gene activation observed in the present study. Taken
together, GSK-3 inhibition caused the rapid dephosphorylation of
c-Jun threonine 239 (allowing DNA binding and transactivation
activity), and subsequent stabilization of the protein.
Effect of c-Jun siRNA on the Induction of GSK-3-regulated
genes
To determine whether c-Jun is required for the induction of the
GSK-3 regulated genes, RNA interference experiments were
performed. Transfection of a specific c-Jun siRNA for 24 hours,
followed by 48 hours of serum starvation resulted in a knockdown
of greater than .90% in T98G cells (Figure 5A). At the end of the
48-hour serum starvation, the effect of the c-Jun knockdown was
tested for both the PDGF and SB-216763 induction of the 8 genes
for which we demonstrated c-Jun binding. Treatment with c-Jun
siRNA decreased the induction of CTGF by PDGF greater than
two-fold (p,0.01) (Figure 5B). The induction CYR61 by PDGF
was also decreased nearly two-fold in the presence of the c-Jun
siRNA, but did not reach statistical significance (p=0.11)
(Figure 5B). RGS2, despite revealing the most dramatic c-Jun
recruitment in the ChIP assays upon PDGF stimulation
(Figure 2B), does not appear to require c-Jun for its PDGF-
mediated induction. RNAi against c-Jun significantly blocked the
induction of CTGF, CYR61 and PLAU (p,0.05) resulting from
inhibition of GSK-3 with SB-216763 (Figure 5C). These
experiments directly demonstrated that c-Jun is required for the
induction of these three genes following GSK-3 inhibition.
Role of AP-1 in the Transcriptional Network Downstream
of GSK-3
Previous studies showed that the GSK-3 regulated genes were
also targeted by CREB [10] and NFkB [12]. We therefore sought
to determine whether there were synergistic or antagonistic
interactions between c-Jun, CREB and NFkB in the transcrip-
tional response of these genes to inhibition of GSK-3. It is
noteworthy in this regard that knockdown of c-Jun resulted in a
greater than 2-fold increase in the induction of NR4A1 upon
inhibition of GSK-3 with SB-216763 (Figure 5C). Thus, rather
than activating transcription of NR4A1, c-Jun appears to interfere
with the induction of this gene, suggesting an inhibitory role for
AP-1 upon NR4A1 transcription. Importantly, NR4A1 is also
targeted by both CREB and NFkB, with siRNA knockdowns of
either of these factors resulting in a significant inhibition of NR4A1
induction [10,12]. It is thus noteworthy that AP-1 and CREB bind
to similar sites [23], and that the AP-1 binding sites at 29 and at
238 (relative to the transcription start site) were also found to be
binding sites for CREB [10]. This suggests that c-Jun may suppress
induction of NR4A1 by sterically interfering with the ability of
CREB to bind at these sites and activate transcription.
We investigated the possible synergistic roles of c-Jun, NFkB
and CREB by performing double knockdown experiments with
pairs of siRNAs for all 3 of these transcription factors. Overall, the
pairwise knockout results were not significantly different from the
effects of siRNA against the individual factors. Representative
results are presented in Figure 6. For example, BHLHB2 has
Figure 4. Effect of GSK-3 inhibition on c-Jun phosphorylation
and stability. T98G cells were rendered quiescent by serum starvation
for 72 hours. Cells were then left untreated (NT), or treated with SB-
216763 or vehicle control (DMSO) for the times indicated. Cell extracts
were immunoblotted in parallel with anti-phospho threonine 239-c-Jun,
pan-c-Jun and b-actin antibodies. Data shown are representative of
three separate experiments. The left and right panels of the
immunoblot in (B) were taken from the same autoradiography film,
and therefore are identical exposure times.
doi:10.1371/journal.pone.0020150.g004
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Figure 5. Effect of c-Jun siRNA on gene induction. A. Knockdown of c-Jun by siRNA. Cells were transfected with either the c-Jun siRNA or a
nonspecific construct (NegCtl), or with no construct added (Mock) and then analyzed by c-Jun and b-actin immunoblots. B. Effect of c-Jun
knockdown on PDGF induction. T98G cells were transfected with a c-Jun or nonspecific negative control siRNA for 24 hours, and then serum starved
for 48 hours. Cells were then stimulated with PDGF for 30 minutes. Expression of the indicated genes was determined by realtime RT-PCR. Data are
presented as fold-change as compared to untreated. Data are means for 4 separate experiments6 S.E. * p,0.01. C. Effect of c-Jun knockdown on SB-
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upstream binding sites for c-Jun and NFkB [12], but induction of
BHLB2 was not significantly inhibited by siRNAs against either
NFkB [12] or c-Jun (see Figure 5) individually. Likewise, induction
of BHLB2 was not significantly inhibited by any of the
combinations of siRNAs against these factors (Figure 6).
CTGF and CYR61 are examples of genes with c-Jun binding sites
whose induction by inhibition of GSK-3 was inhibited by c-Jun
siRNA (see Figure 5). Both of these genes have binding sites for
NFkB and CYR61 also has a binding site for CREB, but the
induction of these genes in response to inhibition of GSK-3 was
not significantly inhibited by either NFkB or CREB siRNAs
[10,12]. Consistent with the results of siRNAs against these
individual factors, induction of these genes was inhibited only by
combinations of siRNAs which included c-Jun siRNA, and the
combinations had no greater effect than c-Jun siRNA alone
(compare Figures 5 and 6). The triple knockdown of these factors
likewise did not affect the SB-216763 induction of BHLHB2,
CTGF or CYR61 (data not shown) as compared to the knockdown
of c-Jun alone.
The results of gene regulation downstream of GSK-3 by AP-1
are integrated with the results of our previous studies on CREB
[10] and NFkB [12] in Figure 7. These 3 factors comprise a
transcriptional network that maintains repression of growth factor-
inducible genes in quiescent cells. Of 12 genes that were inducible
by inhibition of GSK-3 in quiescent T98G cells, 10 were targeted
by at least one of these three transcription factors. Moreover, 4
genes were targeted by all 3 transcription factors and 5 genes by 2
of the 3 factors.
The role of these transcription factors, as assessed by the effects of
siRNA knockdowns, varied for the different target genes in the
network. The induction of 3 of the 10 genes (RGS1, RGS2 and
BHLBH2) was not significantly affected by siRNAs against AP-1,
CREB, or NFkB, either alone or in combination, suggesting that
other transcription factors play a dominant role in regulation of
these genes. Induction of 5 of the other 7 genes was significantly
inhibited by siRNA against 1 of the transcription factors that bound
to their upstream sequences, and induction of 2 genes (FOSB and
NR4A1) was inhibited by siRNAs against both CREB and NFkB.
This suggests that one or two transcription factors play dominant
roles in the induction of different target genes. Interestingly,
induction of NR4A1 was antagonized by AP-1, presumably as a
result of competition for CREB binding as noted above.
AP-1 [15,16], NFkB [24,25] and CREB [26,27] are all known to
play important roles in the induction of immediate-early genes in
response to growth factor stimulation. Furthermore, previous
studies have shown that AP-1 [13,22], NFkB [12,28,29,30] and
CREB [10,31,32,33,34] all can be inhibited by GSK-3. Our results
indicate that these 3 factors comprise a transcriptional network
whose inhibition by GSK-3 plays an important role in maintaining
repression of growth factor-inducible genes during quiescence.
Materials and Methods
Cell Culture and Treatments
T98G human glioblastoma cells were grown in Minimal
Essential Medium (Invitrogen) containing 10% fetal bovine serum
216763 induction. Transfection and starvation were performed as above, and then cells were treated for 1 hour with SB-216763. Data are presented
as fold change as compared to vehicle control (DMSO). Data are means for 4 separate experiments 6 S.E., **p,0.05.
doi:10.1371/journal.pone.0020150.g005
Figure 6. Effect of double siRNAs on gene induction by inhibition of GSK-3. Cells were rendered quiescent and transfected with the
indicated combination of siRNAs. A total of 2.5 nM of each siRNA (5 nM total) was used as compared to 5 nM of negative control siRNA. Knockdown
efficiencies of c-Jun, p65 and CREB were greater than 90% under these conditions. Data are presented as % of the SB-216763 induction as compared
to the induction in the presence of the negative control. All data points are averages of a minimum of n = 3 (except for the p65/CREB combination,
which is n = 2), 6 S.E.
doi:10.1371/journal.pone.0020150.g006
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(Hyclone) and penicillin-streptomycin (Invitrogen). For inhibitor
and growth factor experiments, cells were switched to serum free
media for 72 hours to place the cells in G0 arrest [35]. Arrested
cells were then stimulated with 50 ng/mL human PDGF-BB
(Peprotech) for 30 minutes (or left untreated), or 5 mM SB-216763
(BioMol) or DMSO vehicle for 1 hour.
Chromatin Immunoprecipitation
Chromatin immunoprecipitations were performed as previously
described [10] using 5 mg of anti-c-Jun (Santa Cruz, sc-1696X ),
5 mg of anti-JunD (Santa Cruz, sc-74), or 5 mg of normal rabbit
IgG as a control (Santa Cruz, sc-2027). Salmon sperm DNA/
Protein A agarose bead slurry (50%) immunoprecipitates were
successively washed in low salt, high salt, and lithium chloride
buffers before being washed twice with 16TE (10 mM Tris-HCl,
1 mM EDTA pH 8.0). Immunoprecipitated chromatin was
quantified with real-time PCR (see Figure 1 for mapped amplicons
and Table S1 for precise locations of sites, primers and primer
sequences). MYOG was used as the negative control for all ChIPs.
Immunoblots
Whole cell lysates were electrophoresed in 10% polyacrylamide
gels and transferred to either nitrocellulose or PVDF membranes.
Membranes were then incubated with either anti-JunD (Santa
Cruz, sc-74), anti-JunB (Santa Cruz, sc-73), anti-phospho
threonine 239-c-Jun (Santa Cruz, sc-101720), anti-c-Jun (Santa
Cruz, sc-1696) or anti-b actin (Sigma). Immunoblots were then
incubated with a horseradish peroxidase secondary antibody (Bio-
Rad) followed by visualization using chemiluminescence and
exposure to autoradiography film.
Quantitative RT-PCR
Total RNA was isolated using Trizol (Invitrogen) as recom-
mended by the manufacturer. RNA was used in quantitative real-
time reverse transcription polymerase chain reactions (RT-PCR)
as previously described [11], except using a minimum of 0.75 mg
of total RNA in the reverse transcription reaction. PCR primers
are as previously described [10].
RNA interference
Transfections were performed using pre-designed siRNAs
against p65 (Ambion, S11915), CREB (Ambion, 109994), c-Jun
(Ambion, s7658), or a non-specific negative control (Ambion,
4390843). Shortly before transfection, 105 cells/ml were seeded on
60 mm plates in 4 ml of media containing 10% fetal bovine
serum. Transfection reactions containing 5 nM of siRNA, 20 ml of
HiPerfect (Qiagen) and 100 ml of serum-free media were
incubated for 10 min at room temperature and added drop-wise
onto the cells. For the double knockdowns, 2.5 nM of c-Jun
siRNA, 2.5 nM of p65 siRNA and 2.5 nM of CREB siRNA were
used. Cells were incubated at 37uC, 5% CO2 for 24 hrs and then
serum starved for 48 hrs to induce quiescence prior to treatment
with PDGF-BB for 30 minutes or SB-2167623 for 1 hour.
Starvation times of 48 hrs were used in these experiments to
minimize toxicity from the transfection; gene inductions were
comparable after either 48 or 72 hrs of starvation [10]. Quiescent
cells were then appropriately treated, after which RNA was
extracted and analyzed by real-time RT-PCR.
Supporting Information
Table S1 Chromatin Immunoprecipitation Primers for
Quantitative Real-Time PCR. Real-time PCR primer se-
quences and predicted AP-1 binding site positions are shown. The
‘‘Sites’’ column denotes multiple predicted binding sites in one
gene where applicable. The ‘‘Sites Covered’’ column, in turn,
refers to those sites that are too close to be distinguished from one
another (typically ,250 nucleotides away from each other, the
approximate resolution of the ChIP experiment), and therefore
both (or in some cases, three sites) are tested with one primer set.
* =Experiments with these primer pairs were performed, but the
data is not shown. Results were negative.
(XLS)
Figure 7. Model of the GSK-3 transcriptional network in quiescent cells. The AP-1 data has been combined with that of CREB [10] and NFkB
[12]. Both grey and black arrows indicate ChIP binding by the given factor to the gene’s upstream sequence. Black arrows indicate that siRNA against
the factor blocked induction of the gene in response to SB-216763 treatment greater than two-fold and statistically significant (p,0.05). The blunt-
ended edge between AP-1 and NR4A1 indicates a greater than two-fold inhibition (p,0.05) of induction in the presence of AP-1. RND3 and CCL8 have
been excluded from the illustration, as no ChIP binding nor transcription factor knockdown data indicated any functional connections with AP-1,
NFkB or CREB.
doi:10.1371/journal.pone.0020150.g007
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